Literature DB >> 23556115

Recent developments in management of older patients with acute myeloid leukemia.

Elihu Estey.   

Abstract

Entities:  

Year:  2012        PMID： 23556115      PMCID： PMC3573436          DOI： 10.1177/2040620711434319

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN： 2040-6207


× No keyword cloud information.
  31 in total

1.  A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

Authors:  Todd A Fehniger; Geoffrey L Uy; Kathryn Trinkaus; Alissa D Nelson; Jeffery Demland; Camille N Abboud; Amanda F Cashen; Keith E Stockerl-Goldstein; Peter Westervelt; John F DiPersio; Ravi Vij
Journal:  Blood       Date:  2010-11-04       Impact factor: 22.113

2.  Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

Authors:  Amanda F Cashen; Gary J Schiller; Margaret R O'Donnell; John F DiPersio
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

3.  Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.

Authors:  E H Estey; P F Thall; S Pierce; J Cortes; M Beran; H Kantarjian; M J Keating; M Andreeff; E Freireich
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

4.  Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

Authors:  Elihu Estey; Marcos de Lima; Raoul Tibes; Sherry Pierce; Hagop Kantarjian; Richard Champlin; Sergio Giralt
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

5.  Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

Authors:  Utz Krug; Christoph Röllig; Anja Koschmieder; Achim Heinecke; Maria Cristina Sauerland; Markus Schaich; Christian Thiede; Michael Kramer; Jan Braess; Karsten Spiekermann; Torsten Haferlach; Claudia Haferlach; Steffen Koschmieder; Christian Rohde; Hubert Serve; Bernhard Wörmann; Wolfgang Hiddemann; Gerhard Ehninger; Wolfgang E Berdel; Thomas Büchner; Carsten Müller-Tidow
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

6.  Age and acute myeloid leukemia.

Authors:  Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

7.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

8.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Authors:  Rosemary E Gale; Claire Green; Christopher Allen; Adam J Mead; Alan K Burnett; Robert K Hills; David C Linch
Journal:  Blood       Date:  2007-10-23       Impact factor: 22.113

9.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

Authors:  Richard F Schlenk; Konstanze Döhner; Michael Kneba; Katharina Götze; Frank Hartmann; Francesco Del Valle; Heinz Kirchen; Elisabeth Koller; Jörg T Fischer; Lars Bullinger; Marianne Habdank; Daniela Späth; Silja Groner; Bernhard Krebs; Sabine Kayser; Andrea Corbacioglu; Andreas Anhalt; Axel Benner; Stefan Fröhling; Hartmut Döhner
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

10.  Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.

Authors:  Jean-Valère Malfuson; Anne Etienne; Pascal Turlure; Thierry de Revel; Xavier Thomas; Nathalie Contentin; Christine Terré; Sophie Rigaudeau; Dominique Bordessoule; Norbert Vey; Claude Gardin; Hervé Dombret
Journal:  Haematologica       Date:  2008-10-06       Impact factor: 9.941
View more
  2 in total

1.  Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.

Authors:  Prajwal Chaitanya Boddu; Hagop M Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Srdan Verstovsek; Elias J Jabbour; Koichi Takahashi; Kapil Bhalla; Marina Konopleva; Courtney D DiNardo; Maro Ohanian; Naveen Pemmaraju; Nitin Jain; Sherry Pierce; William G Wierda; Jorge E Cortes; Tapan M Kadia
Journal:  Cancer       Date:  2017-04-07       Impact factor: 6.860

2.  Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.

Authors:  Daniela Damiani; Mario Tiribelli; Donatella Raspadori; Santina Sirianni; Alessia Meneghel; Margherita Cavalllin; Angela Michelutti; Eleonora Toffoletti; Antonella Geromin; Erica Simeone; Monica Bocchia; Renato Fanin
Journal:  Oncotarget       Date:  2015-10-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.